Free Trial

MaxCyte (MXCT) News Today

MaxCyte logo
GBX 342.22 -0.78 (-0.23%)
(As of 03:07 AM ET)
MaxCyte (LON:MXCT) Shares Up 3.4% - Still a Buy?
MaxCyte, Inc. stock logo
MaxCyte (LON:MXCT) Shares Up 3.4% - Here's Why
MaxCyte (LON:MXCT) Stock Price Up 3.4% - Should You Buy?
Stifel Nicolaus Reaffirms Their Buy Rating on MaxCyte (MXCT)
MaxCyte’s Strategic Growth and Cost Efficiency Drive Buy Rating
MaxCyte (MXCT) Initiated with a Buy at Craig-Hallum
MaxCyte Expands Stock Capital Amid Cell Therapy Growth
MaxCyte Director Sells Shares Amid Active Trading
Craig-Hallum Sticks to Its Buy Rating for MaxCyte (MXCT)
MaxCyte, Inc. stock logo
MaxCyte (LON:MXCT) Stock Crosses Below 50 Day Moving Average - Should You Sell?
MaxCyte (LON:MXCT) Share Price Passes Below 50 Day Moving Average - Here's What Happened
MaxCyte, Inc. stock logo
MaxCyte (LON:MXCT) Shares Cross Below 50 Day Moving Average of $325.72
MaxCyte (LON:MXCT) Stock Crosses Below 50-Day Moving Average of $325.72
TD Cowen Reaffirms Their Buy Rating on MaxCyte (MXCT)
MaxCyte, Inc. stock logo
MaxCyte (LON:MXCT) Shares Cross Below 50 Day Moving Average of $332.41
MaxCyte (LON:MXCT) Stock Passes Below Fifty Day Moving Average of $332.41
Stratec SE (SRBZF)
MaxCyte earnings preview: what to expect
MaxCyte, Inc. stock logo
MaxCyte (LON:MXCT) Stock Crosses Above 50 Day Moving Average of $338.25
MaxCyte (LON:MXCT) Share Price Passes Above Fifty Day Moving Average of $338.25
MaxCyte, Inc. stock logo
Insider Selling: MaxCyte, Inc. (LON:MXCT) Insider Sells 5,000 Shares of Stock
MaxCyte, Inc. (LON:MXCT - Get Free Report) insider John Johnston sold 5,000 shares of the stock in a transaction on Tuesday, March 26th. The stock was sold at an average price of GBX 441 ($5.54), for a total value of £22,050 ($27,680.14).
MaxCyte earnings: here's what Wall Street expects
MaxCyte Earnings Preview
MaxCyte, Inc. stock logo
MaxCyte (LON:MXCT) Shares Cross Below Fifty Day Moving Average of $386.32
MaxCyte (LON:MXCT) Share Price Passes Below 50-Day Moving Average of $386.32
MaxCyte May Benefit From Potential Gene Therapy Approval
Get MaxCyte News Delivered to You Automatically

Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter.

Why I'm telling friends to avoid gold stocks (Ad)

Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."

And if you’d like to get your hands on this, here you go, the complete breakdown.

MXCT Media Mentions By Week

MXCT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

MXCT
News Sentiment

0.47

0.65

Average
Medical
News Sentiment

MXCT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

MXCT Articles
This Week

2

0

MXCT Articles
Average Week

Get MaxCyte News Delivered to You Automatically

Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (LON:MXCT) was last updated on 12/18/2024 by MarketBeat.com Staff
From Our Partners